ALTASCIENCES

ACCELERATED DECISION-MAKING

in Drug Development With Altasciences

Make Nonclinical Decisions Sooner

We address potential hurdles by staying **on top of your toxicity and exposure data** so you can make informed decisions promptly.

Reduce Time and Risk

We start **clinical assay development in parallel** with nonclinical studies.

Prepare for Phase II During Phase I

With full-service capabilities, we build **key pharmacodynamic markers and efficacy measures** into the Phase I study design.

Adjust Plan as Data Emerges

Our CRO and CDMO teams have an **ongoing feedback loop**, allowing us to review results and adjust plans in real time.

Altasciences is able to concurrently work on key aspects of your program, planning and adapting alongside you to minimize the gaps you would normally have between GLP and non-GLP studies, pivotal toxicity studies and first-in-human trials, and clinical pharmacology and late phase trials.